Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation.
Elodie RivièreJuliette PascaudNicolas TchitchekSaida BoudaoudAudrey PaolettiBineta LyAnastasia DupréHua ChenAlice ThaiNorm AllaireBernd JaglaMichael MingueneauGaetane NocturneXavier MariettePublished in: Annals of the rheumatic diseases (2020)
SGECs from patients with pSS had better ability than those from controls to induce survival and activation of B lymphocytes. Targeting a single cytokine did not inhibit this effect, whereas leflunomide, BTK or PI3K inhibitors partially decreased B-lymphocyte viability in this model. This gives indications for future therapeutic options in pSS.